| Spotlight |
 |
|
Set against the backdrop of a mixed Q2, Novo is eyeing bolt-ons in favour of transformative acquisitions.
|
| Latest news |
|
|
Reporting 91% growth for Mounjaro, Lilly widened the gap to cardiometabolic rival Novo Nordisk.
|
|
|
Alteogen is set to receive an upfront payment and could earn additional amounts through development, regulatory, and sales milestone payments.
|
|
|
The new arrangement will extend the use of Schrödinger’s technologies, including Bunsen and RetroSynth, throughout BMS’s teams.
|
|
|
How evolving development priorities are helping organisations build manufacturing knowledge from the earliest stages of development.
|
|
|
Premium Content is our new free subscription that provides access to deeper analysis, data-led features and exclusive reports.
|
|
|
|
